Pharmaceutical Product Monograph: Ceftazidime Sodium (1 g, 2 g)
In the pharmaceutical industry, Ceftazidime is a semi-synthetic, broad-spectrum Third-Generation Cephalosporin antibiotic. As a pharmacist and manufacturer, I view this molecule as the “Anti-Pseudomonal Specialist”—it is technically designed to offer significantly higher activity against Gram-negative bacteria than first or second-generation cephalosporins, with a specific chemical “side chain” that makes it a primary weapon against Pseudomonas aeruginosa.
At your WHO-GMP facility in Mumbai, Ceftazidime is a critical “Institutional SKU” for ICU and Critical Care settings. Because it is highly resistant to many bacterial enzymes, it is often the first-line choice for hospital-acquired infections.
Therapeutic Profile: Classification & Use
Ceftazidime is classified as a Beta-lactam antibiotic. Its clinical profile is defined by its ability to penetrate difficult-to-reach tissues and resist bacterial defenses.
| Category | Technical Feature | Clinical Rationale |
| Generation | 3rd Gen Cephalosporin | Broad Gram-negative coverage with diminished Gram-positive activity compared to 1st Gen. |
| Spectrum | Gram-Negative Heavy | The gold standard for Pseudomonas, Enterobacteriaceae, and H. influenzae. |
| CNS Penetration | High (when inflamed) | Crosses the blood-brain barrier effectively, making it a “Go-To” for Gram-negative meningitis. |
| Resistance | Beta-lactamase Stable | Resists hydrolysis by many plasmid-mediated and chromosomal beta-lactamases. |
Mechanism: Cell Wall Synthesis Inhibition
Ceftazidime works by sabotaging the structural integrity of the bacterial “outer shell”:
PBP Binding: The drug enters the bacterial cell and binds with high affinity to Penicillin-Binding Proteins (PBPs), specifically PBP-3.
Peptidoglycan Blockade: It inhibits the final transpeptidation step of cell wall synthesis, preventing the “cross-linking” of the peptidoglycan layer.
Filamentation & Lysis: Technically, this leads to the formation of long, unstable bacterial filaments that cannot divide and eventually undergo osmotic lysis (the cell bursts).
The Pharmacist’s “Technical Warning”
The “Pseudomonas” Paradox: As a pharmacist, I must emphasize that while Ceftazidime is great for Pseudomonas, it has very poor activity against Staphylococcus aureus (MRSA) and Enterococci. It should not be used for suspected Staph infections.
Renal Adjustment: Technically, Ceftazidime is excreted almost entirely by the kidneys. For patients with a $GFR < 50 \text{ mL/min}$, the dose must be strictly reduced to avoid neurotoxicity (confusion, seizures).
Penicillin Cross-Reactivity: About 5–10% of patients with a severe Penicillin allergy may also react to Ceftazidime. Always perform a skin test if the history is unclear.
Chemical Incompatibility: Do not mix Ceftazidime and Aminoglycosides (like Amikacin) in the same IV bag; they can physically precipitate and inactivate each other.
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your facility in Mumbai:
The “Carbonate” USP: On your digital marketplace, highlight your Ceftazidime with Sodium Carbonate blend. Ceftazidime is naturally insoluble; adding Sodium Carbonate is the technical “Buffer” that allows it to dissolve into a clear, injectable solution.
The “CO2” Effect: Warn B2B clients that upon reconstitution, Carbon Dioxide ($CO_2$) gas is released. The vial will develop internal pressure, which is technically normal for this product and not a sign of contamination.
Stability for Export: Ceftazidime is heat-sensitive. Your Cold-Chain (2–8°C) storage and light-protected packaging are essential for maintaining a 24-month shelf life in Zone IVb tropical regions.
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Ceftazidime 1 g and 2 g vials to support your registration in international B2B hospital tenders.